The Future of Genomic Medicine in the Cloud
Featuring CLC bio and IBM Research
Event Date: March 19, 2014
High-performance computing (HPC) and storage solutions developed for the technical community are required to process the data produced by Next Generation Sequencing that is doubling every five months. (Baker M., Nature Methods 7, 2010, 495). In the four phases in a sequencing project: (a) Experimental design and sample collection, (b) Sequencing (c) Data management and (d). Downstream analysis, it takes a highly optimized HPC platform to keep pace with the genomic data analysis. CLC bio, a Qiagen Company, has worked with IBM Life Science industry experts to optimize their software, Genomics Server, to deliver an easy to use and maintain data management environment to their customers.
Although the capability to rapidly and cheaply sequence the genome is important, this is not the primary goal of a sequencing project. Genome data correlated with corresponding phenotype information, image analysis, and published scientific discovery, will drive scientific discovery. IBM Research has been actively engaged in Genomic Medicine creating unique and sophisticated algorithms that are bringing new insights to the industry. CLC bio, a Qiagen Company, and IBM Research will give perspectives on the industry and give examples of work we are doing to help researchers analyze the wide spectrum information and to speed the analytics so that the promise of personalized medicine can be realized.
Janis Landry-Lane, WW Deep Computing Lead – Life Sciences, Higher Education
Ajay Royyuru, PhD., Director, IBM Computational Biology - IBM Research
Mikael Flensborg, Director, Global Partner Relations - CLCbio a Qiagen Company
Lenny Liebmann, Moderator - IT Business Edge